PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Godebu, Elana ^a,b   Muldong, Michelle ^a,b,c   Strasner, Amy ^a,b,c   Wu, Christina N ^c   Park, Seung C ^d   Woo, Jason R ^a,b   Ma, Wenxue ^c   Liss, Michael A ^a,b   Hirata, Takeshi ^e   Raheem, Omer ^a,b   Cacalano, Nicholas A ^f   Kulidjian, Anna A ^a,c,g   Jamieson, Christina A M ^a,b,c  

^a Rady Children's Specialists of San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Wonkwang University School of Medicine   (South Korea)

^e OKAYAMA UNIVERSITY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deprivation therapy; Bone metastatic prostate cancer; Castrate resistant; Tumor microenvironment; Xenograft

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; ANILIDE; ANTIANDROGEN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTHROPLASTY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG TREATMENT FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PCSD1 MODEL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BONE NEOPLASMS; DISEASE MODEL; MOUSE; ORCHIECTOMY; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; MALE; MICE; NITRILES; ORCHIECTOMY; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 84908084173     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0275-1     Document Type: Article

References (23)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014, 64:9-29. 10.3322/caac.21208, 24399786.
2. Desireddi NV, Roehl KA, Loeb S, Yu X, Griffin CR, Kundu SK, Han M, Catalona WJ. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007, 70:950-955. 10.1016/j.urology.2007.06.1119, 18068453.
3. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8:357-368. 21556025.
4. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014, 12:686-718. 24812137.
5. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790. 10.1126/science.1168175, 19359544.
6. Swanson GP. Primary hormone therapy for locally advanced prostate cancer. Curr Urol Rep 2006, 7:225-232. 10.1007/s11934-006-0025-x, 16630526.
7. Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 2010, 4:147-152. 10.1097/SPC.0b013e32833bd913, 20592607.
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005. 10.1056/NEJMoa1014618, 21612468.
9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, De Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, De Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. 10.1056/NEJMoa1207506, 22894553.
10. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013, 14:1193-1199. 10.1016/S1470-2045(13)70424-8, 24075621.
11. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014, 65:30-36. 10.1016/j.eururo.2013.06.042, 23849416.
12. Culig Z. Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother 2014, 15:1427-1437. 10.1517/14656566.2014.915313, 24890318.
13. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011, 17:4854-4861. 10.1158/1078-0432.CCR-11-0815, 21632851.
14. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 2011, 9:185-5876-9-185.
15. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013, 12(3):316-328. Epub 2013 Jan, 10.1016/j.stem.2012.12.011, 23333150.
16. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One 2012, 7(6):e39725. Epub 2012 Jun 29, 10.1371/journal.pone.0039725, 22768113.
17. Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, Lieberman JR. Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med 2008, 49(3):414-421. Epub 2008 Feb 20, 10.2967/jnumed.107.045666, 18287261.
18. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med 2014, 12:30. 10.1186/1479-5876-12-30, 24475900.
19. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19(5):575-586. doi:10.1016/j.ccr.2011.04.008, 10.1016/j.ccr.2011.04.008, 21575859.
20. Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc Natl Acad Sci U S A 2013, 110(39):15710-15715. 10.1073/pnas.1218168110, 24019458.
21. Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene 2013, 32(34):3992-4000. Epub 2012 Sep 17, 10.1038/onc.2012.412, 22986532.
22. Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol 2012, 26(5):716-735. Epub 2012 Mar 28, 10.1210/me.2011-1130, 22456196.
23. Jamieson CAM, Yamamoto KR. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci U S A 2000, 97(13):7319-7324. 10.1073/pnas.97.13.7319, 10860997.